779 results about "Oxidative damage" patented technology

This invention comprises administering to a human or animal in need of treatment an effective amount of an antioxidant lipoic acid derivative and/or pharmaceutically acceptable salts and solvates thereof for the treatment or prevention of pathological (inflammatory, proliferative and degenerative diseases, e.g. diabetes mellitus, atherosclerosis, Alzheimer's disease and chronic viral diseases) and non-pathological (e.g. skin aging and wrinkle formation) conditions caused by oxidative damage. Methods of synthesizing novel antioxidant lipoic acid derivatives and their use in preventing or treating diseases or conditions caused by oxidative stress and other free radical mediated conditions are described. Another aspect of this invention is the use of these antioxidant compositions for the protection of skin from damage caused by ultraviolet radiation and dessication, and to provide improved skin feel by desquamating, cleansing and clarifying the skin. The compositions described in this invention increase cellular viability of epidermal cells, promote cytoprotection, and decrease the production of inflammatory mediators such as inflammatory cytokines in these cells. The antioxidant compositions are incorporated into sunscreen products, soap, moisturizing lotions, skin toners, and other skin care products.

Cytoprotective compounds, many of which are benzofuran derivatives are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

The invention provides a method for reducing oxidative damage in a mammal, a removed organ, or a cell in need thereof. The method comprises administering an effective amount of an aromatic cationic peptide. The aromatic cationic peptide has (a) at least one net positive charge; (b) a minimum of three amino acids; (c) a maximum of about twenty amino acids; (d) a relationship between the minimum number of net positive charges (p_m) and the total number of amino acid residues (r) wherein 3p_m is the largest number that is less than or equal to r+1; (e) a relationship between the minimum number of aromatic groups (a) and the total number of net positive charges (pt) wherein 3a or 2a is the largest number that is less than or equal to p_t+1, except that when a is 1, p_t may also be 1; and (f) at least one tyrosine or tryptophan amino acid.

Cytoprotective compounds, many of which are phenolic derivatives characterized by a substituted phenol having certain conjugated bonds, are useful in the treatment of certain ischemic or inflammatory conditions, including but not limited to stroke, myocardial infarction, congestive heart failure, and skin disorders characterized by inflammation or oxidative damage. They are also useful in the manufacture of pharmaceutical and cosmetic formulations for the treatment of such conditions.

In one aspect, the present invention relates to an implantable device for detecting the presence or concentration of an analyte in an aqueous environment in vivo. The device includes a macromolecule that comprises a copolymer of: a) one or more indicator component monomers which individually are not sufficiently water soluble to permit their use in an aqueous environment for detecting the presence or concentration of said analyte; b) one or more hydrophilic monomers; and c) one or more catalytic antioxidant monomers; such that the macromolecule is capable of detecting the presence or concentration of the analyte in an aqueous environment. The presence of the catalytic antioxidant reduces or prevents oxidative damage to the macromolecule.

The invention provides novel methods for treating disease based upon the medicinal use of lipids and phospholipids covalently bound to physiologically acceptable monomers or polymers. Phosphatidylethanolamine moieties conjugated to physiologically acceptable monomers and polymers (PE conjugates) manifest an unexpectedly wide range of pharmacological effects, including stabilizing cell membranes; limiting oxidative damage to cell and blood components; limiting cell proliferation, cell extravasation and (tumor) cell migratory behavior; suppressing immune responses; and attenuating physiological reactions to stress, as expressed in elevated chemokine levels. The surprisingly manifold pharmacological properties of the PL-conjugates allow for the invention, disclosed herein, of novel methods for the treatment of a diverse range of disease states, including obstructive respiratory disease, including asthma; colitis and Crohn's disease; central nervous system insult, including blood brain barrier compromise, ischemic stroke, and multiple sclerosis; contact dermatitis; psoriasis; cardiovascular disease, including ischemic conditions and prophylaxis for invasive vascular procedures; cellular proliferative disorders, including anti-tumor vasculogenesis, invasiveness, and metastases; anti-oxidant therapy; hemolytic syndromes; sepsis; acute respiratory distress syndrome; tissue transplant rejection syndromes; autoimmune disease; viral infection; and hypersensitivity conjunctivitis. The therapeutic methods of the invention include administration of phosphatidylethanolamine bound to carboxymethylcellulose, heparin, hyaluronic acid, polyethylene glycol, and Polygeline (haemaccel). Disclosed herein are also new compounds comprised of phospholipid moieties bound to low molecular weight monomers and dimers, including mono- and disaccharides, carboxylated disaccharides, mono- and dicarboxylic acids, salicylates, bile acids, and fatty acids.

The present invention provides compositions and methods for protecting tissues and organs from damage during transplantation or from acute ischemia due to, e.g., injury or surgery. The compositions protect the tissue or organ from acidosis, oxidative damage, ischemia and repurfusion injury while the organ is isolated from the normal circulation or receives inadequate arterial flow.

Indolepropionamide (IPAM) and related compounds, pharmaceutical or dietary compositions thereof and methods of using said compounds are disclosed for use as a preventative or therapeutic treatment for many conditions related to oxidative damage. Oxidative damage increases in aging and age related disorders and is widespread in many neurodegenerative conditions including Alzheimer's disease, Parkinson's disease and others. Indolepropionamide is a potent anti-oxidant and anti-aging molecule, with superior properties as compares to previously known compounds.

A method for alleviating a symptom of chemotherapy in a subject comprises identifying a subject undergoing chemotherapy and then administering a therapeutically effective amount of a GH/IGF-1 Axis inhibitory composition to the subject. Typically, the levels of IGF-1 and/or GH in the subject are monitored as well as chemotherapy related symptoms. A method of alleviating oxidative damage, cellular damage including mutations, and insulin resistance in a subject is also provided.

The invention relates to compositions and methods of treatment using an iron chelator, an antioxidant, estrogen, and/or combinations thereof, optionally, linked to a nanoparticle, to treat a subject in need thereof. The compositions and methods may be used to restore or protect the normal functions of osteoblast and osteoclast by depleting iron and inhibiting oxidative damage. The compositions and methods may also be used to increase the bone formation rate in a subject.

The present invention relates to topical compositions containing a dispersion of composite particles. Each of such composite particles contains one or more core particles encapsulated or entrapped in a polymeric shell. At least some of the core particles are formed of a material capable of causing generation of reactive oxygen species (ROS). Each of the composite particles further contains: (1) a first antioxidant co-encapsulated or co-entrapped with the core particles inside the polymeric shell for quenching or scavenging ROS generated in the vicinity of the core particles, and (2) a second antioxidant coated over the polymeric shell for preventing or reducing oxidative damage to the skin, such as lipid peroxidation. The particle dispersion of the present invention therefore can be readily formulated into topical sunscreen compositions with organic sunscreen agents susceptible to oxidative decomposition or degradation to provide improved protection against skin damage caused by exposure to UV light.

A method for treating skin, reducing oxidative damage to a skin cell, reducing lipoxygenase (LO) activity in a skin cell, reducing cyclooxygenase (COX) activity in a skin cell, reducing tumor necrosis factor alpha (TNF-α) in a skin cell, or reduction matrix metalloproteinase enzyme activity in a skin cell comprising contacting skin or a skin cell with an aromatic skin-active ingredient.

The invention discloses a new application of sodium hydrosulfide for promoting germination of wheat seeds under the stress of heavy metals, namely, the application is that the sodium hydrosulfide is taken as a sprout-promoting agent of germination in the soil polluted by heavy metals of Al<3+>, Cd<2+>, Cr<3+>, Cr<6+>, Pb<2+>, Hg<2> and the like. The invention can effectively improve the germinability of the wheat seeds under the stress of heavy metals, and induces the seeds to germinate fast and regularly. Research proves that the sodium hydrosulfide of the hydrogen sulfide donor is adopted to preprocess the wheat seeds, which can remarkably induce the activity expression of hydrolytic enzyme of amylase, protease, lipase and the like, in the seeds, enhances the oxygenolysis of storage matter, relieves the oxidative damage caused by the stress of the heavy metals in the seeds and maintains the lower membrane lipid overoxidation level in the seeds and the seedlings, thus being beneficial to the normal growth of embryo and radicle. The invention solves the key problem of restoring the production of the wheat in the areas polluted by heavy metals, has simple operation; the needed reagent is single and is easy to be obtained.

Gene panels, microarrays and biomarker panels relating to genes and gene products associated with age-related oxidative damage to skin, and transcriptional profiling-based methods for identification and evaluation of cosmetic agents for prevention, reversal, or reduction of oxidative damage to skin. Cosmetic agents and compositions comprising the cosmetic agents, capable of inducing nrf2-mediated activation of the antioxidant response element to increase expression of Phase 2 enzymes, methods for restoring optimal redox status to skin employing the agents, and methods for identifying and evaluating cosmetic agents acting via the nrf2-mediated mechanism.

The invention relates to Isopentenyl-oxyl substituted dehydrogenized silybin ether and the preparation method and the application thereof. The compound has the activity of eliminating extracorporeal extracorporeal 1-diphenyl-2-picrylhydrazyl radical, the activity of obviously inhibiting the generation of lipid peroxide induced by radical and the function of powerfully preventing the damage of therat adrenal pheochromocytoma PC12 cells due to the hydrogen peroxide, i.e. the function of preventing the oxidative damage of the PC12 cells simulating the brain nerve cells, thereby playing a positive role in preventing the brain cell tissue oxidation and brain never oxidation and preventing and treating the senile dementia and other neurodegenerative diseases. The pharmacodynamic result shows that 7-site substituted dehydrogenized silybin ether can be expectantly used for preparing the medicament for preventing and treating the neurodegenerative diseases.

Compounds, formulations, and methods are provided containing the choline ester of a reducing agent, especially lipoic acid or derivatives thereof. The compounds may be administered via a topical ocular route to treat or prevent oxidative damage.

The invention provides a mangiferin salt, in particular to a salt formed in the basic amino acid, organic amine and inorganic alkaline matter capable of being accepted by the mangiferin and medicine. The salt can solve the dissolubility, improve the pharmacological activity and be used for curing or curing auxiliary the diseases related closely to the oxidative damage. The general formula of the structure refers to the drawing, wherein, R is the basic amino acid, organic amine or inorganic alkaline metallic ion.